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Abstract
Background: A number of different malaria vaccine candidates are currently in pre-clinical or clinical development. Even
though they vary greatly in their characteristics, it is unlikely that any of them will provide long-lasting sterilizing immunity
against the malaria parasite. There is great uncertainty about what the minimal vaccine profile should be before registration
is worthwhile; how to allocate resources between different candidates with different profiles; which candidates to consider
combining; and what deployment strategies to consider.
Methods and Findings: We use previously published stochastic simulation models, calibrated against extensive
epidemiological data, to make quantitative predictions of the population effects of malaria vaccines on malaria
transmission, morbidity and mortality. The models are fitted and simulations obtained via volunteer computing. We
consider a range of endemic malaria settings with deployment of vaccines via the Expanded program on immunization
(EPI), with and without additional booster doses, and also via 5-yearly mass campaigns for a range of coverages. The
simulation scenarios account for the dynamic effects of natural and vaccine induced immunity, for treatment of clinical
episodes, and for births, ageing and deaths in the cohort. Simulated pre-erythrocytic vaccines have greatest benefits in low
endemic settings (,EIR of 10.5) where between 12% and 14% of all deaths are averted when initial efficacy is 50%. In some
high transmission scenarios (.EIR of 84) PEV may lead to increased incidence of severe disease in the long term, if efficacy is
moderate to low (,70%). Blood stage vaccines (BSV) are most useful in high transmission settings, and are comparable to
PEV for low transmission settings. Combinations of PEV and BSV generally perform little better than the best of the
contributing components. A minimum half-life of protection of 2–3 years appears to be a precondition for substantial
epidemiological effects. Herd immunity effects can be achieved with even moderately effective (.20%) malaria vaccines
(either PEV or BSV) when deployed through mass campaigns targeting all age-groups as well as EPI, and especially if
combined with highly efficacious transmission-blocking components.
Conclusions: We present for the first time a stochastic simulation approach to compare likely effects on morbidity, mortality
and transmission of a range of malaria vaccines and vaccine combinations in realistic epidemiological and health systems
settings. The results raise several issues for vaccine clinical development, in particular appropriateness of vaccine types for
different transmission settings; the need to assess transmission to the vector and duration of protection; and the
importance of deployment additional to the EPI, which again may make the issue of number of doses required more critical.
To test the validity and robustness of our conclusions there is a need for further modeling (and, of course, field research)
using alternative formulations for both natural and vaccine induced immunity. Evaluation of alternative deployment
strategies outside EPI needs to consider the operational implications of different approaches to mass vaccination.
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Introduction
The demand for an effective vaccine against Plasmodium
falciparum malaria has stimulated the development of candidates
targeted against pre-erythrocytic stages of the parasite, others
against blood stages or toxins that cause disease, and yet more
against the sexual stages [1]. It is not obvious what level of efficacy
needs to be achieved for a malaria vaccine to be worthwhile since
even vaccines that only partially protect might offer substantial
health benefits, given the enormous burden of P. falciparum
morbidity and mortality in endemic areas [2,3]. In fact, the
vaccine that is most advanced in clinical development, RTS,S, has
shown only partial protection against infection and disease in
clinical trials [4,5].
The impact of a vaccine will depend not only on average
efficacy, but also on the extent of heterogeneity of the host
response including its duration. Other determinants include the
natural force of infection and its seasonal variation, the vaccination
coverage which could be achieved, especially in the most exposed
and the most vulnerable groups and the efficacy and coverage of
other malaria control interventions, preventive or curative. As for
all public health interventions, safety, cost, operational feasibility
and acceptability also need to be considered when deciding which
candidates to prioritize, which ones to consider for combination,
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strategies.
Field trials of malaria vaccines are generally designed to evaluate
the effect on morbidity or on infection rates in the vaccinated
population [6], without considering effects on transmission or the
long-term dynamics of immunity. In contrast, modeling of malaria
vaccines has concentrated on analysing transmission, and in
particular identifying the conditions for controlling or interrupting
it [7–11]. We have developed stochastic simulation models of the
natural history and epidemiologyofP. falciparum malaria [12,13] that
bring all these factors together and apply them to the simulation of
malaria vaccination [14]. In a first phase of the project we
concentrated on the likely epidemiological effects [14] and cost-
effectiveness [15] of pre-erythrocytic vaccines when delivered in
areas of stable malaria via the Expanded Program on Immunization
(EPI). We now report on the extension of these simulations to
consider also blood-stage vaccines, mosquito stage transmission
blocking vaccines and combination vaccines, delivered via different
modalities. The purpose of this work is to assess the effectiveness of
different vaccines at different transmission settings, to examine what
minimal profile of a vaccine is appropriate and to prompt discussion
of alternative delivery modalities.
Results
Effects on transmission
In line with our previous simulations, we find that moderately
efficacious pre-erythrocytic vaccines applied via EPI do not have
any substantial effect on malaria transmission, (results not shown),
because only a small proportion of the population is protected. If
the initial efficacy of PEV is high then effects on transmission are
observed for EPI and EPI with boosters (Figure 1a, c, e). If a high
efficacy PEV is delivered via EPI with mass vaccination with high
coverage, herd immunity with substantial transmission effects are
achieved (Figure 1a, c, e).
We observe elimination with PEV alone, at very high efficacy
and mass vaccination coverage and at the lowest transmission
levels (Figure 1a), where PEV is more effective than BSV (see
below). However, these models do not consider immigration and
importation of new cases, which is far removed from any real life
epidemiological situation. In other PEV scenarios where we
observe some effect on transmission without interruption, the
reduction is followed by rebounds in infectivity (Figure 1a, c, e).
This is a consequence of the deferral of infection events for such a
vaccine. Reduction in incidence of blood stage infection for
younger hosts makes them vulnerable to high-density parasitae-
mia, which is most infectious, when they are older. The simulation
assumes mosquitoes bite these larger hosts more frequently [19],
thus leading to a increase in transmission.
For highly efficacious BSV, we observe effects on transmission,
particularly at high transmission settings (Figure 1b, d, f). These
reductions are slightly less than those observed for PEV with the
same initial efficacy, and BSV does not interrupt transmission in any
scenario. Rebound effects on infectivity occur for BSV only when
delivered via mass vaccination (Figure 1 b, d, f). Combinations of
PEV and BSV produce reductions in transmission slightly greater
than the individual vaccines alone, and at higher transmission a
rebound occurs, as for PEV alone (results not shown).
As expected, for vaccine combinations with MSTBV we observe
greater reductions in transmission over PEV or BSV alone
(Figure 2 for PEV with MSTBV, other results not shown). In
contrast to PEV alone, we observe no rebound in infectivity for
delivery modes EPI and EPI with boosters and over 20 years,
MSTBV combination vaccines delivered via EPI with boosters
reduce transmission to a slightly greater extent than in the absence
of the boosters. Under EPI with mass vaccination at 95%
coverage, MSTBV combinations reduce transmission to zero at
low transmission. In higher transmission settings we observe
substantial effects on transmission and then periodical rebounds
over 20 years (Figure 2).
Elimination is generally simulated at the lower initial transmis-
sion intensities with vaccine combinations containing MSTBV
and/or for highly efficacious vaccines delivered via EPI with mass
vaccination. In the simulations that we examined in detail (results
not shown) elimination is more likely when the homogeneity
parameter is very low or if the vaccine half-life is very large.
The time to elimination, dependent on initial vaccine efficacy, is
considered in Figure 3, for those transmission settings and delivery
modalities (mass vaccination at 95% coverage) where elimination
was achieved within20 years. Here, eachvaccine has a half-life of 10
years and homogeneity value of 10. Combinations with MSTBV
achieve elimination for lower initial efficacies of the other vaccine
component and for a wider range of transmission settings than PEV
orPEV with BSV. Interpretation of thetimeto elimination given the
vaccine profile is difficult because of the discrete nature of the mass
vaccination campaigns. In general, the time to elimination given this
mass vaccination schedule does not strongly depend on the initial
efficacy except at very high efficacy levels. In the lowest transmission
settings with very high coverage and high initial efficacy of the
MSTBV component, elimination is observed even with very low
initial efficacies of the other components.
Effects on morbidity and mortality
Pre-erythrocytic vaccines. Effect of vaccine characteristics: The
numbers of events averted per 1000 person-years by a pre-
erythrocytic vaccine, when distributed via EPI (Figure 4a–c at the
reference transmission setting, seasonal transmission based on
Namawala, Tanzania) are similar to those reported in our previous
analyses [14] despite the small changes to the health system and
the epidemiological model. Even moderately efficacious PEVs
delivered via EPI may avert substantial numbers of clinical events
(Figure 4a–c and Table S1, Supplementary material). The curves
relating effectiveness to vaccine efficacy for a range of transmission
settings, (Figure 5) are concave, indicating that an increase in
efficacy has a greater than proportional effect on events averted,
due to the impact on transmission.
As reported previously, the effectiveness of PEV depends
strongly on the duration of protection for vaccines with half-life
less than 2–3 years [14] deployed by EPI or EPI with boosters.
However, there is only a modest increase in the number of disease
episodes or deaths averted, if the half-life is extended from 2 years
to 5 years (Figure 4d–f, Figure S1d–f, Figure 6d–f).
Previous simulations showed that a PEV averts a higher
proportion of clinical episodes and deaths if there is heterogeneity
in the response to vaccination among individuals, namely if PEV
concentrates its effects in some individuals (low value for the
homogeneity parameter), who thus never become infected, than
one that spreads protection more evenly across the population.
This result is confirmed here (Figure 4g–i and Figure S1g–i), and
the effect, although small, is observed over all transmission settings
(results not shown) and is particularly true in mass vaccination
scenarios for low transmission settings.
Effect of duration of observation and transmission intensity: By using a 10
year period we obtain slightly more favourable predictions than
found previously for a 20 year horizon, since effects of deferral of
episodes become most evident in the second decade after the start
of the program [14]. This is particularly the case for higher
transmission settings (results not shown) and for severe malaria
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setting of EIR of 21, the percentage of deaths averted remains
fairly constant over the course of the follow-up, and a PEV of 50%
primary efficacy is predicted to avert about 13% of all deaths
under EPI alone, about 15% under EPI with boosters and about
18% and 21% with EPI and mass vaccination of coverage 50%
and 70%, respectively (Fig. S2, Supplementary material). For all
vaccine distribution systems, the proportion of uncomplicated
episodes that are averted in this transmission setting is lower than
for deaths and severe episodes (Figure S1a–c).
Effect of different delivery modalities: Across all transmission settings,
the addition of booster doses to the EPI vaccine schedule results in
minimal improvement to the cases averted by the reference PEV
(Figure 4, Figure S1, Figure 5a–f). However a benefit of booster
doses is evident when the half-life is short. Dissemination of
vaccines via mass campaigns, supplementing EPI, also has little
impact on overall effect when the efficacy is low, but at low
transmission, high efficacy and high vaccine coverage, when
elimination is achieved, all but the earliest episodes are averted.
There is also a substantial benefit of mass vaccination in medium
Figure 1. Effect of PEV (a,c,e) and BSV (b,d,f) on infectivity to vector over 20 years when delivered via EPI (black), EPI with boosters
(blue) and EPI with 95% mass vaccination (red) for transmissions settings of EIR 5.25 (a,b), 21 (c,d) and 168 (e,f). Results obtained
assuming a vaccine efficacy of 80%, half-life of 10 years and homogeneity value of 10. Note that the blue and black lines almost overlap.
doi:10.1371/journal.pone.0003193.g001
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(Figure 4, Figure 5). In contrast, at very high transmission settings,
mass vaccination averts fewer cases than EPI or EPI plus booster
delivery, especially at low vaccine efficacies and for severe
episodes. This is because PE vaccines delay infections for the
whole population under high and moderate mass vaccination
coverage (Supplementary Figure S2). This is also true for very low
vaccine half-life (results not shown).
Figure 2. Effect of PEV with MSTBV (a,b,c) on infectivity to vector over 20 years when delivered via EPI (black), EPI with boosters
(blue) and EPI with 95% mass vaccination (red) for transmissions settings of EIR 21 (a), 42 (b) and 168 (c). Results obtained assuming a
vaccine efficacy of 52%, half-life of 10 years and homogeneity value of 10.
doi:10.1371/journal.pone.0003193.g002
Figure 3. Time to elimination given initial efficacies (x-axis) of vaccine for different transmission settings (square indicates
combination with MSTBV and circle without). All results are for vaccines delivered via EPI with mass vaccination, no elimination is achieved
under these conditions for vaccines delivered via EPI or EPI with boosters. Results obtained assuming vaccine half-life of 10 years and homogeneity
value of 10.
doi:10.1371/journal.pone.0003193.g003
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transmission intensity: In low transmission settings, low or
moderately efficacious blood-stage vaccines avert comparable
proportions of disease episodes and deaths to those averted by
PEV with comparable efficacy for all delivery modalities.
However, at moderate to high efficacy levels, BSVs avert slightly
less uncomplicated cases than PEV, but slightly more
severe episodes and deaths (compare Figures 5 and S3 and
Figures 7, S4, 8a–c, g–i). In transmission settings comparable to
the reference level or higher, BSV of low to moderate efficacies
avert higher numbers of cases and deaths than PEV. (Figure 7, S4,
8 a–c, g–i).
The curves relating the events averted (not shown) and
effectiveness of BSVs to the primary efficacy (Figure S3) are close
to straight lines, indicating that the effectiveness is almost directly
proportional to the efficacy. Probably, the effect on transmission of
highly efficacious BSV, (Figure 1b, d, f) is less important for
averting disease and death than is the case for PEV.
As with PEV, the effectiveness of BSV strongly depends on the
duration of protection for vaccines with half-life less than about 2–
Figure 4. Effect of initial efficacy (a–c), vaccine half-life (d–f) and degree of heterogeneity (g–i) on the number of events averted per
1000 person years by PEV for the reference transmission setting of EIR 21. Results obtained assuming vaccine efficacy of 52%, a vaccine
half-life of 10 years and homogeneity value of 10, unless the values are varied along the x-axis. Vaccines are distributed via EPI (circles), EPI with
boosters (*) and EPI with 70% mass vaccination (squares).
doi:10.1371/journal.pone.0003193.g004
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beyond 5 years has little impact.
As with PEV, the results predict a very small improvement if the
vaccine effect is concentrated in some individuals. (Figure S7 a–c).
Effect of different delivery modalities: The addition of boosters to the
EPI for all transmission settings has minimal effect on the
effectiveness of BSV, though we observe small gains by adding
boosters to the EPI at very high vaccine efficacies, or short half-
lives. In general, the effect of adding mass vaccination is much
greater (Figure 7, S4 and 8a–c).
Combination vaccines and MSTBV. BSV plus PEV:
Combining BSV with PEV improves effectiveness over PEV
alone for all transmission settings and vaccine deliveries (compare
Figures 7, S4, 8 m–o with g–i and Supplementary Table S1). The
greatest difference is seen at high transmission, and this can be
attributed to the high effectiveness of BSV alone in these settings.
In fact, in high transmission settings, the combination of PEV with
BSV is less effective than BSV alone due to the poor effectiveness
of PEV at such transmission settings. In contrast, the combination
is more effective than BSV alone in low transmission settings
(compare Figures 7, S4, 8 a–c and g–i with m–o and
Supplementary Table S1).
MSTBV: MSTBV show minimal effectiveness when used alone,
except when delivered via mass vaccination, at very high coverage
Figure 5. Effect of initial efficacy on effectiveness of PEV for different transmission settings delivered via EPI (a–c), EPI with
boosters (d–f) and EPI with 70% mass vaccination (g–i). Results obtained assuming a vaccine half-life of 10 years and homogeneity value of 10.
doi:10.1371/journal.pone.0003193.g005
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initial efficacy point for the other vaccines in the combinations).
Combinations of MSTBV with PEV or BSV do not appear to
improve the effectiveness of the vaccines alone when delivered via
EPI or EPI with boosters over 10 years (Figures 7 and S4 compare
d–f with a–c and j–l with g–i), and over 20 years only slightly more
events are averted (results not shown). There is also little to be
gained by triple combination delivered through EPI (Figures 7 and
S4, compare p–r with m–o). In contrast, with mass vaccination,
combinations with MSTBV are much more effective (Figure 8).
This is the case for all transmission settings and for all events
averted, except in the case of highly efficacious BSV combined
with MSTBV at very high transmission. In such a scenario the
effectiveness of BSV is slightly higher than for BSV combined with
MSTBV for severe disease and as coverage of the mass campaign
decreases, this effect is also seen for uncomplicated cases. This is
because MSTBV blocks transmission and hence natural immunity
development and thus, in the absence of elimination, delays severe
disease even with BSV protection.
The biggest improvement to effectiveness by adding MSTBV to
BSV, PEV or BSV with PEV, is observed at very low transmission
settings, where almost all deaths, severe and uncomplicated events
tend to a situation where they may all be averted over the 10 years
for very high efficacy and mass vaccination coverages, suggesting
Figure 6. Effect of vaccine half-life on effectiveness of PEV for different transmission settings delivered via EPI (a–c), EPI with boosters
(d–f) and EPI with 70% mass vaccination (g–i). Results obtained assuming a an initial vaccine efficacy of 52% and homogeneity value of 10.
doi:10.1371/journal.pone.0003193.g006
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(Figure S8).
The results indicating significant improvement to the number of
cases averted for vaccine combinations with MSTBV is achieved
onlywhendeliveredviaEPIwithmassvaccination(Figure8),arenot
surprising when one considers that delivery of vaccines via EPI and
EPI with boosters target only infants and children up to four years
and that once a child misses an EPI dose they do not receive any
furtherdoses.In suchsituationstheeffectof MSTBVisconcentrated
in age groups of the population that contribute little to transmission.
Over a 20 year time period, we do observe an increase in
effectiveness by combination vaccines with MSTBV, compared to
those without, especially with increasing half-life (results not shown).
With mass vaccination, the effectiveness of combination vaccines
continues to increase with duration of protection even for half-lives
beyond 5 years, in contrast to other delivery modalities (compare
Figure S6d–f, j–l, q–s). Additionally,for combinations with MSTBV
at high coverage levels in low to moderate transmission settings
elimination is approached, or achieved depending on the coverage
level (Figure S6). Like for single vaccines, a high degree of
heterogeneity improves effectiveness, but this effect is far more
pronounced for combinations (Figure S7).
Figure 7. Effect of initial efficacy on effectiveness of all vaccines for different transmission settings delivered via EPI (BSV (a–c),
BSV/TBV (d–f), PEV (g–i), PEV/TBV (j–l), BSV/PEV (m–o) and BSV/TBV (p–r)). Results obtained assuming a vaccine half-life of 10 years and
homogeneity value of 10.
doi:10.1371/journal.pone.0003193.g007
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most contexts, EPI with booster does not significantly improve
cumulative effectiveness or cases averted over EPI alone. In
contrast, mass campaigns increase effectiveness even at relatively
low coverage, especially in low transmission settings. However, in
high transmission settings the increase in effectiveness of delivery
via EPI with mass vaccination is not as large. For very high
transmission, a PEV with low efficacy is less effective under EPI
with mass vaccination compared to EPI alone (compare Figure 5
a–c with g–i and Supplementary Table S1).
Under EPI with mass vaccination, increasing coverage increases
effectiveness and cases averted in most transmission scenarios. The
exceptions are in higher transmission settings for severe episodes
averted by BSV with MSTBV, PEV alone and PEV with
MSTBV, where very high coverage levels are associated with
small reductions of effectiveness (Figure 9). Although higher
coverage of a mass vaccination campaign generally predicts more
benefits in terms of episodes averted, a cost effectiveness analysis
will offer more insights on what constitutes a feasible level of
coverage.
Figure 8. Effect of initial efficacy on effectiveness of all vaccines for different transmission settings delivered via EPI with 70-%
mass vaccination (BSV (a–c), BSV/TBV (d–f), PEV (g–i), PEV/TBV (j–l), BSV/PEV (m–o) and BSV/TBV (p–r)). Results obtained assuming a
vaccine half-life of 10 years and homogeneity value of 10.
doi:10.1371/journal.pone.0003193.g008
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We have presented the results of stochastic simulations of the
likely population effects of different malaria vaccine profiles,
distributed via different distribution modalities with the aim to
assess their usefulness in multiple transmission settings. We
examine the effects in controlling morbidity and mortality as well
as impact on malaria transmission, thus bridging a gap between
field trials of efficacy and malaria transmission models. The
simulation results have implication for vaccine developers
concerning which vaccines to develop and with what minimal
profile, and in which transmission settings these vaccines are likely
to provide most benefit. The results highlight the benefit of
considering alternative methods of deployment outside of EPI. All
these considerations need to be considered by vaccine developers
along with issues of safety, immunogenicity, feasibility, and costs
that fall outside the scope of this analysis.
Our previous simulations of PEV, aligned with the results of field
trials of the RTS,S/AS02A vaccine [18], suggest that such vaccines
distributed via EPI will lead to partial protection broadly distributed
across the vaccinated population but that no-one is completely
protected, and little herd immunity [18]. The new simulations
indicate that major gains in effectiveness are unlikely with such
vaccines, even if deployed via mass vaccination strategies. In contrast,
Figure 9. Effectiveness of vaccines given different levels of mass vaccination coverage when delivered via EPI with community wide
campaigns for different transmission settings (BSV (a–c), BSV/TBV (d–f), PEV (g–i), PEV/TBV (j–l), BSV/PEV (m–o) and BSV/TBV (p–
r)). Results obtained assuming an initial vaccine efficacy of 52%, a vaccine half-life of 10 years and homogeneity value of 10.
doi:10.1371/journal.pone.0003193.g009
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important herd immunity effects in all delivery modes, especially in
mass vaccination situations and in low transmission settings.
However, over longer time periods a rebound in infectivity and
transmission is expected, and thus fewer cases would be averted, due
to deferral of events into older, more infectious, hosts.
The simulations suggest that PEV in general will be much more
effective in low transmission settings than in high transmission
settings. If delivered via EPI with mass vaccination in high
transmission settings and high coverage our models predict that
low efficacy PEV may even lead to increases in severe morbidity
over a 10 year period (or longer) by shifting the morbidity patterns
to those observed in lower exposure settings, i.e. higher risk in
higher age-groups. This predicted negative benefit of low
efficacious PEV highlights a possible risk involved with introducing
PEV in high transmission settings.
The model for the action of asexual BSV represents one of the
more tentative components of our integrated model. Although one
candidate BSV has shown a substantial effect on parasite densities
[20], the assumption that this effect is a constant over different
parasite densities in different epidemiological contexts is clearly a
simplification. Very likely, effective BSV has complex effects on
parasite dynamics, and improved within-host models are needed
to capture these. Such a model is currently under development.
With this note of caution, the simulations also support the
development of BSV candidates as morbidity and mortality
control tools, but imply that these are unlikely to have very
substantial effects on transmission, unless they achieve very high
levels of efficacy in controlling parasite densities, and/or if
deployed via mass vaccination. In contrast to PEV, BSV deployed
via EPI are predicted to be more effective in higher transmission
settings than at low transmission. The converse was observed for
BSV delivered via EPI with mass vaccination.
More generally, there is a need for further alternative simulations
of both natural and vaccine induced immunity, including models of
natural boosting. When field data become available they may
require us to consider exposure-dependence of vaccine efficacy or
intrinsic age dependence of the primary effect of the vaccine.
In comparing different vaccine types it is important to remember
that the measure of efficacy used to define the simulated vaccines
differs for the different vaccine types; a 50% efficacy BSV is
equivalent to a 50% efficacy PEV only in the sense that both
represent imperfect vaccines. The present simulations of combina-
tion vaccines, with matched values of the efficacy parameters for the
PEV and BSV components represent only one of an infinite number
of possible combinations, and it will be most useful to simulate actual
candidates, once their likely profiles become available. It seems
unlikely that there would be much interest in combining very
efficacious PEV or BSV with a rather poor efficacy partner.
CombinationvaccineswithPEVandBSVcomponentsseemtohave
some potential in mass vaccination scenarios, even when efficacy is
modest, but do not look much more promising for use in the context
of EPI or EPI with boosters than the best of the individual
components. In general, the effectiveness of such combinations
seems similar to or lower than that of BSV in high transmission
settings. This could be attributed to the PEV component lowering
the exposure of vaccinated individuals so that the combination
vaccine effectiveness is similar to that at a slightly lower transmission
level for BSV alone (see Figure 7). At lower levels of transmission the
addition of BSV to PEV results in small gains with slightly more
events averted than that of PEV alone. However, in practice, the
difficulties of epidemiological stratification, seasonal and epidemic
variation and the variable effects of vector control might make the
use of such combinations rational.
The most realistic scenarios for MSTBV however are clearly
situations where high efficacy MSTBV might be deployed in mass
vaccination to supplement the effects of moderate efficacy PEV or
BSV. This approach is supported by the simulation results. In such
situations a rather poor effectiveness of the PEV or BSV
component on its own may become very substantial depending
on the transmission intensity. So far we simulated combinations
with matched durations of efficacy, however it may well be the
case that MSTBVs have only very short-term effects because of an
absence of natural boosting [21], so there is a need also to simulate
combinations with high efficacy but short half-life MSTBV.
A number of the mass vaccination scenarios predict local
elimination of the parasite. However, malaria is much easier to
eliminate in computer simulations than in reality. This is particularly
the case because transmission in nature is highly heterogeneous and
this would be particularly important in low transmission settings
[22,23] so an adequate model for transmission heterogeneity would
be essential for making useful predictions concerning local
elimination. Our models currently allow for some heterogeneity in
host response to infection and in infectiousness [24,25] but not in
susceptibility to infection. Furthermore, our simulations do not
consider the effect of imported infections, which would have to be
modelled taking into consideration the effectiveness of surveillance
and heterogeneities in epidemiological receptivity.
Interestingly, we found that PEV vaccines in which the effect is
concentrated in some individuals are more likely to achieve
elimination. This arises because of the convex shape of the
effectiveness vs initial efficacy curve (e.g. figure S1a–c) which
implies, following Jensen’s inequality [26] that variation in the
efficacy will increase the average effectiveness. By an analogous
argument we expect that heterogeneity in the vaccine half-life
reduces effectiveness (see concave curve in figure S1d–f).
The simulations we present here should have implications for
vaccine developers concerning the definition of minimal require-
ments for malaria vaccines to be used in public health. A PEV or
BSV with a half-life of efficacy of less than 2–3 years will be of
limited value and assessment of duration of protection is of great
importance. Unfortunately Phase II trials are generally not
designed to estimate duration. Since incidence declines steeply
with age in young children, claims that efficacy is sustained in
extended follow-ups [27,28] are based on little data. Conversely,
heterogeneities between individuals in susceptibility or vaccine
‘take’ lead to violation of proportional hazard assumptions [29]
which appear as waning in apparent efficacy [18].
In addition to possible effects on transmission, vaccine
developers would also be interested in determining whether
substantial herd immunity effects are likely, and thus clinical
development plans need to evaluate effects on transmission to the
vector. We have found that, as could be expected, substantial
transmission impact is generally achieved only if EPI delivery is
supplemented by mass campaigns. Developers thus need to
consider how vaccines are to be deployed. Probably, an important
criterion for whether vaccines can be relatively easily deployed
widely outside EPI is whether protection can be achieved with
only 1 or 2 doses. In this respect, further analysis needs to focus on
scenarios that are aligned with realistic distribution systems, using
field data to identify realistic correlations between vaccination at
successive rounds, rather than assuming these to be independent,
and to assess what are feasible intervals between rounds.
Ultimately, malaria vaccines will be deployed as part of
integrated control strategies. We thus plan further analyses to
explore the interactions of vaccination with other malaria control
interventions and the implications for resource allocation and
management within the health system.
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Epidemiological Model
We base our simulations of vaccines on our previously described
model for the natural history and epidemiology of P. falciparum
malaria [12]. This model uses an underlying within-host model
based on detailed studies of the course of parasite densities in
patients, who were treated for neurosyphilis in the 1950s with
inoculations of malaria parasites. Morbidity, mortality, and
transmission to the mosquito vector are treated as stochastic events
with disease incidence related to the simulated parasite densities, and
human demography is simulated with an algorithm that maintains
the age structure of a typical rural African population.
For the present simulations we have recalibrated the model, using
a genetic algorithm to parameterise it to 61 field scenarios from sub-
Saharan Africa, comprising data on seasonality, age-patterns of
infection, parasite density, clinical episodes, severe malaria and
mortality[13]. The optimisation process made use of the Berkeley
Open Infrastructure for Network Computing (BOINC; http://
boinc.berkeley.edu/) whichenables volunteer members of the public
to run simulations of the field scenarios via links at www.
malariacontrol.net, allowing parallel processing of many different
computer intensive tasks. In addition to several thousand iterations
for fitting, we make use of volunteer computing for over 32000
iterations/scenarios to produce the simulation results in this paper.
Case management model
The simulations of the effects of vaccine interventions use a case
management model, including both formal and informal treat-
ment, based on that of a previous study to simulate existing case
management in Tanzania [16]. To align our models with recent
policy changes we modify this model to assume Artemisinin-based
Combination Therapy (ACT) to be the first treatment for
uncomplicated malaria while keeping with our previous model
calibration that implied 4% of all fever attacks lead to official care
for malaria. This change has implications, in terms of reduced
rates of severe disease, sequelae and death, and also has an impact
on transmission intensity. For our reference case, the model
assumes that the ACT has a cure rate of 85%, which applies to
90% of patients that comply with the treatment schedule, and no
effect for non-compliers [17]. Equity and heterogeneities in health
systems are also important and are topics of later investigations,
but beyond the scope of this work.
Simulation of vaccines
Each simulated vaccine is characterised by an average initial
efficacy, which is reached after completion of a vaccination
schedule of 3 doses and thereafter decays exponentially. For the
reference vaccine initial efficacy 52% after the third dose we
assume efficacies for dose 1 and 2 used previously, namely 40%
and 46% respectively [14]. For all other scenarios we assume the
protective efficacy to increase linearly with the dose number, so
that the efficacy after one dose is one third of the assumed
maximum efficacy. To allow for heterogeneity in individuals’
response to vaccination, we assign initial values for efficacy, which
are drawn from a beta-distribution [14]. We quantify the degree of
variation in response by the parameter b of the beta distribution
and refer to this as the homogeneity parameter, which takes a high
value when the vaccine effect is distributed evenly, and conversely
a low value when the effect is concentrated in some individuals. All
simulated vaccines are delivered at the pre-specified ages, but we
consider a range of coverage values for vaccination (Table 1) to
allow for individuals who do not complete the full course of
vaccination.
(i) Pre-erythrocytic vaccines (PEV). We assume pre-
erythrocytic vaccines lead to a reduction in the proportion of
sporozoite inocula that lead to blood stage infection, where the
efficacy is equal to the proportional reduction in incidence of
infection. This model is justified by analysis of the effects recorded
in trials of the RTS,S vaccine [18].
(ii) Blood stage vaccines (BSV). The immediate effect of a
blood stage vaccine is assumed to be reduction in parasite density
levels at each time step, where efficacy is equal to the proportional
reduction.
(iii) Mosquito stage transmission blocking vaccines
(MSTBV). We model mosquito-stage transmission blocking
vaccines by defining the efficacy to be the proportion by which
the probability that a mosquito becomes infected from any one
feed is reduced. We assume the efficacy of MSTBV to be
proportional to the number of doses. This if the initial efficacy
after the third dose is 95%, for first and second doses we assume
initial efficacies of 32% and 63%, respectively.
(iv) Combination vaccines. We consider combination
vaccines of PEV with MSTBV, BSV with MSTBV, BSV with
PEV and also a combination of all three. In each case we assume
PEV and BSV to be matched in the initial efficacy and in rate of
decay. Since it is unlikely that MSTBV with only moderate
efficacy will be developed, we consider combinations of PEV, BSV
and of PEV-BSV with high efficacy MSTBV, and thus assume an
MSTBV initial efficacy after the third dose of 95%. The rate of
decay of MSTBV is matched to that of the other vaccine
components.
Table 1. Summary of vaccination scenarios investigated







Delivery modality EPI (1,2,3 Months)
EPI with booster 1,2,3,4 years after the
last EPI dose,
EPI+Campaign: Mass vaccination 3
doses at start of intervention period,
then 1 dose at 5,10,15 years.
Vaccine coverage EPI: 89% 3rd dose; 95% 1st dose
EPI with booster: 99% of previously
vaccinated
EPI+Campaigns: varying levels of
coverage from 0% to 95% are
considered.
Initial protected efficacies after
dose 3
0.1 to 1 (stepsize 0.1) (reference 0.5)
Half live of protective efficacy 0.5, 1, 1.5, 2, 2.5, 5, 10, 20, no decay
(years)
Between host variation in initial
protective efficacy*
b= 0.01, 10, 100000
Transmission intensity EIR (infectious bites per annum)=5.25,
10.5, 21, 42, 84, 168
*parameter b
Figures in bold represent the value used for the reference scenario
doi:10.1371/journal.pone.0003193.t001
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We model three delivery modalities:
(i) EPI. The first is the delivery through the EPI according to
the usual DTP3 schedule (children 1, 2, 3 months of age).
(ii) EPI with booster. In this delivery modality, booster doses
are added to the normal EPI schedule with booster doses at 1,2,3,4
years after the last EPI schedule. We assume that the effect of a
booster dose of vaccine is to restore the protective efficacy to that
achieved after the 3
rd dose in the same individual.
(iii) Mass vaccination with EPI catch-up. The third
delivery modality combines the delivery of the vaccine to infants
through EPI and a population-wide mass vaccination campaign
with three doses at the beginning of the intervention period
followed by additional mass vaccinations with a single dose after 5,
10, and 15 years. The protective efficacy of the vaccine is assumed
to increase linearly up to dose 3. Additional doses restore the
efficacy to that achieved at dose 3.
Vaccine coverage
Under delivery modality (i),the vaccination coverage is as detailed
in Table 1. This corresponds to that used in our previous models
[14], in which the coverage of full vaccination is that reported in
Tanzania for three doses of diphtheria tetanus pertussis–hepatitis B
(DTP-HBV) vaccine in the year 2003, which was 95%, for the first
dose and 89% for the third. Under delivery modality (ii) we assume
that only thosethat receive the thirdEPI dose receive a boosterdose.
Coverage for booster doses is 99% of those that did not miss any of
the previous vaccine doses. It is unlikely that those that miss an EPI
dosewillreceive booster doses, and if included in the booster regime,
it is unlikely further benefit would be predicted since coverage of the
thirdEPIdoseisrelativelyhigh(89%)andboosterdosagecoverageis
very high (99%). For delivery modality (iii) we investigate different
levels of coverage, ranging from 0% to 95%. We assume that in the
initial campaign the percentage of the population covered at each of
the three doses is the same and that after 5, 10, and 15 years, the
same percentage of the population (all ages), but not necessarily the
same individuals, receives a single dose.
Measurement of effects of vaccination programs
The simulated scenarios cover all three vaccine types, and the
three combinations, delivered through the three modalities at a
range of coverage levels (Table 1). We also consider 6 different
transmission intensities (Table 1). For each vaccine and combina-
tion, for each delivery strategy, coverage level and transmission
intensity, we start from a reference set of assumptions and vary one
of the efficacy parameters (initial efficacy, half-life and heteroge-
neity parameter), at a time. The parameters of Table 1 were
chosen to consider a wide range of vaccine profiles, and thus to
examine the effect of varying elements of half-life, efficacy and
heterogeneity in response. The effect of each of these variations is
evaluated by simulating the malaria dynamics in a population of
100,000 people over a 20 year period. Each simulation is repeated
3 times using different seeds to initialize the random number
generator, and each of these simulations is compared with an
independent simulation of a control population with no vaccine,
but with the same human demography, baseline transmission
setting, and health system. In general, variation between seeds in
results is small. Measures of variation for predictions for different
seed values are available on request.
Measures of health gains
The main analyses consider the aggregated effects over the
first 10 years of the vaccination program. We consider the effect
of each vaccine on simulated values of a standard set of
epidemiological outcomes in the whole population (not just those
vaccinated): the number of uncomplicated malaria episodes, the
number of severe malaria episodes and the number of deaths
caused by malaria. For each of these outcomes we compute the
number of events averted per 1000 person-years by comparing
the vaccine simulation with the corresponding control simulation.
We define the effectiveness as the proportion of events of each
type that are averted. In addition, at each time point of the 20
years of the simulation we consider the proportion of mosquitoes
that become infected at each feed as a measure of the level of
transmission. We present predictions via plots of outcomes or
estimates of average effectiveness for particular scenarios (Table
S1, Supplementary material). Residual stochastic variation is
small and consequently we do not present statistical significant
tests.
Supporting Information
Figure S1 Effect of initial efficacy (a–c), vaccine half-life (d–f)
and degree of heterogeneity (g–i) on the effectiveness of PEV for
the reference transmission setting of EIR 21. Results obtained
assuming vaccine efficacy of 52%, a vaccine half-life of 10 years
and homogeneity value of 10, unless the values are varied along
the x-axis. Vaccines are distributed via EPI (circles), EPI with
boosters (*) and EPI with 70% mass vaccination (squares).
Found at: doi:10.1371/journal.pone.0003193.s001 (1.04 MB TIF)
Figure S2 Effect of initial efficacy on effectiveness of PEV for
different transmission settings delivered via EPI with mass
vaccination for 0% (a–c), 10% (d–f), 30% (g–i), 50% (j–l),7 0%
(m–o) and 90% (p–r) coverage. Results obtained assuming a
vaccine half-life of 10 years and homogeneity value of 10.
Found at: doi:10.1371/journal.pone.0003193.s002 (1.46 MB TIF)
Figure S3 Effect of initial efficacy on effectiveness of BSV for
different transmission settings delivered via EPI (a–c), EPI with
boosters (d–f) and EPI with 70% mass vaccination (g–i). Results
obtained assuming a vaccine half-life of 10 years and homogeneity
value of 10.
Found at: doi:10.1371/journal.pone.0003193.s003 (1.16 MB TIF)
Figure S4 Effect of initial efficacy on effectiveness of all vaccines
for different transmission settings delivered via EPI and boosters
(BSV (a–c), BSV/TBV (d–f), PEV (g–i), PEV/TBV (j–l), BSV/
PEV (m–o) and BSV/TBV (p–r)). Results obtained assuming a
vaccine half-life of 10 years and homogeneity value of 10.
Found at: doi:10.1371/journal.pone.0003193.s004 (1.34 MB TIF)
Figure S5 Effect of vaccine half-life on effectiveness of all
vaccines for different transmission settings delivered via EPI (BSV
(a–c), BSV/TBV (d–f), PEV (g–i), PEV/TBV (j–l), BSV/PEV (m–
o) and BSV/TBV (p–r)). Results obtained assuming an initial
vaccine efficacy of 52% and homogeneity value of 10.
Found at: doi:10.1371/journal.pone.0003193.s005 (1.14 MB TIF)
Figure S6 Effect of vaccine half-life on effectiveness of all
vaccines for different transmission settings delivered via EPI with
70% mass vaccination (BSV (a–c), BSV/TBV (d–f), PEV (g–i),
PEV/TBV (j–l), BSV/PEV (m–o) and BSV/TBV (p–r)). Results
obtained assuming an initial vaccine efficacy of 52% and
homogeneity value of 10.
Found at: doi:10.1371/journal.pone.0003193.s006 (1.36 MB TIF)
Figure S7 Effect of the degree of heterogeneity on effectiveness
of all vaccines for different transmission settings delivered via EPI
(BSV (a–c), BSV/TBV (d–f), PEV (g–i), PEV/TBV (j–l), BSV/
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vaccine half-life of 10 years and homogeneity value of 10.
Found at: doi:10.1371/journal.pone.0003193.s007 (1.14 MB TIF)
Figure S8 Effect of initial efficacy on effectiveness of vaccine
combinations with MSTBV for different transmission settings
delivered via EPI with mass vaccination for 0% (a–c), 10% (d–f),
30% (g–i), 50% (j–l),7 0% (m–o) and 90% (p–r) coverage. Results
obtained assuming a vaccine half-life of 10 years and homogeneity
value of 10.
Found at: doi:10.1371/journal.pone.0003193.s008 (1.62 MB TIF)
Table S1 Effectiveness (%) of each vaccine or combination over
10 years
Found at: doi:10.1371/journal.pone.0003193.s009 (0.13 MB
DOC)
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